Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Improving Patient Adherence Integral to Expanding the U.S. Antipsychotic Medications Market
- Business Editors/Health/Medical Writers PALO ALTO, Calif.--BUSINESS WIRE--June 3, 2004 The introduction of new antipsychotic drug formulations is likely to improve compliance rates among the mentally ill by providing patients with additional treatment options. Currently, lack of medical compliance can be attributed to the adverse side effects of antipsychotics...
- Research articles 2004-06-03
- Chemistry Professor Testifies about Schizophrenia Drug in Lilly Patent Trial.
- By Jeff Swiatek, The Indianapolis Star Knight Ridder/Tribune Business News Feb. 11--A Purdue University chemistry professor said Tuesday the invention of Zyprexa by Eli Lilly and Co. was hardly obvious and came at a time when most of the world's major drug companies...
- Research articles 2004-02-11
- A Lilly-ImClone Deal May Offer the Drama that CEO Lechleiter Craves
- Today came the news that Eli Lilly is one of the mystery suitors in the ImClone deal that Bristol-Myers Squibb was just booted from. If CEO John Lechleiter were to scoop up ImClone -- thus bolting on the cancer specialist's pipeline to replace the absence of its...
- Blog posts 2008-09-29
- More Zyprexa Trouble for Lilly as Insurers Want Money Too
- Eli Lilly still faces a ton of legal action on its Zyprexa mismarketing, despite having paid a $1.4 billion settlement recently to state prosecutors and a separate $1.2 billion to settle individual patient plaintiffs. That leaves insurance companies, who believe they were defrauded out of money when...
- Blog posts 2009-01-21
- In Zyprexa Settlement, Lilly Fritters Away 7.2 Percent of Revenues
- Eli Lilly is close to settling criminal and civil charges related to its mismarketing of Zyprexa for $1.4 billion, the New York Times reports. The settlement will mean that Lilly will have disgorged $3.1 billion in charges, mostly for Zyprexa, since 2006. That's about 7.2 percent of its revenues over...
- Blog posts 2009-01-21
- How Eli Lilly Waved Goodbye to $3.1 Billion
- How Eli Lilly Waved Goodbye to $3.1 BillionRE: How Eli Lilly Waved Goodbye to $3.1 BillionJim, I think what they are saying is that the exceptional hopefully non-recurring charge expressed as a percentage of current quarter sales is not a meaningful ratio. The meaningful number would be the cummulative...
- Discussion threads 2008-10-27
Additional Resources
- Eli Lilly settles Zyprexa suit for $1.42-billion
- NEW YORK — Drug maker Eli Lilly is pleading guilty to a charge that it illegally marketed anti-psychotic drug Zyprexa for off-label use, and will pay a combined $1.42-billion (U.S.) to settle civil suits and end the criminal investigation. The Indianapolis-based company will pay $800-million to settle civil suits, including...
- News items 2009-08-07
- Lilly Apologizes for Wrongful Zyprexa Promotion; Still Shovelling Cash Into Settlement Furnace
- Another quarter, another $80 million in "not meaningful" charges for Eli Lilly. The company reported its Q4 2008 results yesterday, and as usual the income statement contained a lump devoted to money lost on "asset impairments, restructuring and other special charges." With the new charge for $80...
- Blog posts 2009-01-30
- Lilly's Zyprexa shot faces FDA delay
- Eli Lilly announced Wednesday that the FDA has delayed approval of a long acting version of its schizophrenia drug olanzapine pending a proposal for a Risk Evaluation and Mitigation Strategy REMS. The company says it will submit the proposal in the "near future," but did not offer a time period. "We cannot...
- News items 2009-08-07
- Lilly - Viva Zyprexa contd..... the payoff
- Eli Lilly, the drug company, is expected to agree as soon as Thursday to pay $1.4 billion to settle criminal and civil charges that it illegally marketed its blockbuster antipsychotic drug Zyprexa for unauthorized use in patients particularly vulnerable to its risky side effects.Multimedia Today's Business: Gardiner Harris on the Eli...
- News items 2009-08-07
- Hersh & Hersh Announces Creation of Settlement Fund for Eli Lilly Zyprexa Lawsuits
- San Francisco plaintiff rights law firm Hersh & Hersh today announced the creation of a settlement fund for personal injury lawsuits brought on behalf of people who were prescribed the Eli Lilly drug Zyprexa and developed diabetes and other related illnesses. Hersh & Hersh filed the first Zyprexa lawsuit in...
- Research articles 2005-06-10
- Suit: Lilly Touted Zyprexa for Alzheimer's Knowing It Was Ineffective; Sales Reps Had $10K Off-Label Promo Budgets
- Eli Lilly knew in 1995 that Zyprexa was ineffective for treating Alzheimer's and dementia in the elderly but promoted it for that purpose anyway, according to a lawsuit. The suit also claims that each Zyprexa sales rep had a $10,000 budget that it used to pay pharmacies and doctors for...
- Blog posts 2009-06-12
- Indiana-Based Eli Lilly Discounts Possible Zyprexa Link to High Blood Sugar.(Knight Ridder/Tribune Business News)
- Jan. 6--Eli Lilly and Co. is reanalyzing data from thousands of patients because it's concerned about reports that its schizophrenia drug Zyprexa might be linked to high blood-sugar levels. Jan. 6--Eli Lilly and Co. is reanalyzing data from thousands of patients because it's concerned...
- Research articles 2001-01-08
- Ivax Begins Generics Battle Over Eli Lilly's Zyprexa.(Brief Article)
- STILL REELING from its defeat with Barr Laboratory over a generic version of Prozac fluoxetine, Eli Lilly is facing yet another generic threat, this time for its blockbuster antipsychotic drug, Zyprexa olanzapine. Last week, Ivax Corporation fi STILL REELING from its defeat with Barr...
- Research articles 2001-03-05
- Lilly Q1: Price Rises, End of Zyprexa Woes Boost the Numbers
- With its costly Zyprexa settlements out of the way, Eli Lilly got back to business as usual: Raising drug prices. And it seems to have paid off. Lilly's Q1 revenue was $5 billion, up from $4.8 billion the year before (but down sequentially from mid-2008 when quarterly revenues touched $5.2...
- Blog posts 2009-04-20
- The 340B Prime Vendor Program Adds Eli Lilly's Zyprexa(R) to Its Growing List of Branded Drugs for Participants
- The 340B Prime Vendor Program, managed by HealthCare Purchasing Partners International® HPPI announced today that it has added Eli Lilly & Company to contract to extend discounts for Zyprexa® olanzapine, an atypical antipsychotic medication proven effective for treating schizophrenia, acute mixed or manic episodes of bipolar disorder, and maintenance treatment...
- Research articles 2007-02-19
- U.S. District Court in Indiana Upholds Zyprexa Patent
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that Judge Richard Young of the U.S. District Court for the Southern District of Indiana ruled in favor of the validity of Eli Lilly's patent on anti-psychotic drug, ZyprexaR.
- Research articles 2005-04-14
- U.S. District Court to Rule on Zyprexa Patent Case on April 14th AT 5:50 P.M. EDT
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced today that the U.S. District Court for the Southern District of Indiana has stated that Judge Richard Young will render his decision in the ZyprexaR patent case of Eli Lilly and Company v. Zenith Goldline Pharmaceuticals IVAX et al on Thursday, April...
- Research articles 2005-04-13
- Pharma Roundup: Pfizer Re-Slices Organizational Pie, Lilly Dishes Out Zyprexa Settlement, and More
- Pfizer reorganizes; Lilly to pay $62 million fine over Zyprexa; biotech losing talent to clean tech; Consumer Reports blacklists 20 drugs for seniors by John Maas
- Blog posts 2008-10-07
- Questions Over Zyprexa Clinical Trial Data Underscore Need for Congress to Act Now on Drug Safety Legislation
- To: NATIONAL EDITORSContact: Susan Herold or Bill Vaughan, +1-202-462-6262, both of Consumers Union WASHINGTON, April 25 /PRNewswire-USNewswire/ -- Today's news that the Food and Drug Administration is examining whether the maker of Zyprexa failed to submit clinical trial data about the harmful side effects of the antipsychotic drug underscores the...
- Research articles 2007-04-25
- << Previous
- page 1 of 1
- Next >>
